Stats by Source
Total, split by cell line (COSMIC CL / DepMap / PubMed) vs tissue (COSMIC primary tissue)
Total = all mutations for this gene across every source.
Cell line = COSMIC Cell Lines Project + DepMap + PubMed.
Tissue = COSMIC primary-tissue (patient tumour) samples.
Total can exceed cell line + tissue: COSMIC tissue-derived models sit only in global, and a peptide can be shared across both.
| Total | Cell line | Tissue | |
|---|---|---|---|
| Mutations | 156 | 38 | 116 |
| Samples | 152 | 36 | 114 |
| Peptides | 120 | 32 | 94 |
Function
PAWR · Pro-apoptotic WT1 regulator
This gene encodes a tumor suppressor protein that selectively induces apoptosis in cancer cells through intracellular and extracellular mechanisms. The intracellular mechanism involves the inhibition of pro-survival pathways and the activation of Fas-mediated apoptosis, while the extracellular mechanism involves the binding of a secreted form of this protein to glucose regulated protein 78 (GRP78) on the cell surface, which leads to activation of the extrinsic apoptotic pathway. This gene is located on the unstable human chromosomal 12q21 region and is often deleted or mutated different tumors. The encoded protein also plays an important role in the progression of age-related diseases. [provided by RefSeq, Aug 2017].
Isoforms & Proteins
1 transcript · UniProt mapping is sequence-verified (AA-safe)
Each Ensembl transcript (ENST) this gene is mutated on, with its matched UniProt accession.
The mapping is sequence-verified: the UniProt sequence is identical to the transcript translation, so amino-acid positions line up exactly. A * marks an unreviewed (TrEMBL) entry.
Counts are mutations and unique mutant peptides on each transcript.
| Transcript | UniProt | Mutations | Peptides |
|---|---|---|---|
| ENST00000328827 | Q96IZ0 | 156 | 120 |
Gene Properties
Recurrent Mutations
All 120 amino-acid changes on canonical ENST00000328827 · needle height = samples · drag the mini-map to zoom
A lollipop / needle plot – the standard way to show recurrent mutations along a protein (as used by cBioPortal and MutationMapper).
X-axis = amino-acid position in the protein.
Needle height & head size = how often that exact amino-acid change was observed (its recurrence). Tall/large heads are mutational hotspots.
The most recurrent changes are labelled; hover any needle for the change, position and counts.
Mutation frequency across cancer types
% of samples with a missense/complex mutation in PAWR · cell line vs tissue
For each cancer type, the fraction of samples that carry at least one missense/complex mutation anywhere in PAWR – counted as distinct samples (a sample counts once no matter how many mutations it has).
Split into cell line and tissue; each cell shows mutated / total and the percentage. Cohorts with <20 samples are omitted. Ordered by combined frequency.
| Cancer type | Cell lines | Tissue samples |
|---|---|---|
| T-Lymphoblastic Leukemia | 1/40 2% | 0/0 0% |
| Acute Myeloid Leukemia | 2/90 2% | 0/0 0% |
| Endometrial Carcinoma | 2/42 5% | 7/612 1% |
| Cervical Carcinoma | 0/35 0% | 3/422 1% |
| Melanoma | 2/210 1% | 11/1899 1% |
| Colorectal Carcinoma | 3/143 2% | 18/3239 1% |
| Thyroid Gland Carcinoma | 0/45 0% | 10/1592 1% |
| Bladder Carcinoma | 1/58 2% | 5/956 1% |
| Neuroendocrine Tumour | 1/154 1% | 3/577 1% |
| Ovarian Carcinoma | 2/109 2% | 4/998 0% |
| Other Sarcomas | 2/69 3% | 2/699 0% |
| Squamous Cell Lung Carcinoma | 2/57 4% | 2/810 0% |
| Burkitts Lymphoma | 0/32 0% | 1/196 1% |
| Kidney Carcinoma | 4/85 5% | 4/1862 0% |
| Small Cell Lung Carcinoma | 0/9 0% | 3/752 0% |
| Meningioma | 1/3 33% | 0/252 0% |
| Head and Neck Carcinoma | 1/85 1% | 5/1574 0% |
| Other Solid Cancers | 2/94 2% | 3/1515 0% |
| Non-Small Cell Lung Carcinoma | 2/304 1% | 3/1390 0% |
| Plasma Cell Myeloma | 0/44 0% | 1/305 0% |
| Esophageal Squamous Cell Carcinoma | 0/51 0% | 6/2550 0% |
| Biliary Tract Carcinoma | 1/54 2% | 1/950 0% |
| Pancreatic Carcinoma | 0/89 0% | 3/1611 0% |
| Gastric Carcinoma | 1/74 1% | 2/1809 0% |
| B-Lymphoblastic Leukemia | 2/55 4% | 2/2640 0% |
| Breast Carcinoma | 2/144 1% | 3/3264 0% |
| B-Cell Non-Hodgkins Lymphoma | 1/88 1% | 3/2534 0% |
| Prostate Carcinoma | 0/13 0% | 3/2105 0% |
| Esophageal Carcinoma | 0/23 0% | 1/769 0% |
| Hepatocellular Carcinoma | 0/46 0% | 3/2210 0% |
Mutation Distribution
Where PAWR is mutated · all tissues, split by cell line vs tissue
How many mutations in PAWR were found in each tissue, across the whole database.
Each bar is a tissue (cell-line and tissue names are merged to the standard tissue), split into cell line and tissue (patient tumour) contributions.
This shows the cancer-context where this gene is recurrently altered.
GTEx Expression
Median TPM across 54 healthy tissues
Median gene expression (TPM) in normal, non-cancer human tissues from the GTEx project.
Useful for judging tumour specificity – a strong neoantigen target ideally comes from a gene with low expression in healthy tissues.
Scroll or drag the mini-axis below the chart to browse all tissues.
Mutations
All 156 mutations in PAWR
Every mutation record for this gene, across all samples and sources.
The Sample column links to the cell line (cell-line samples) or the tissue type (tissue samples).
Use the Type / Source filters, the search box, and column sorting to explore; each CAN-IMMUNE ID opens the full mutation & peptide view.
| ID | Sample | Transcript | AA Change | CDS | Type | Source | Mutant Peptide | Wild-type Peptide |
|---|